Results 1 to 5 of 5

Thread: NeoTherapeutics Reverse Stock split - 25:1

  1. #1
    Senior Member mk99's Avatar
    Join Date
    Jul 2001
    Location
    toronto, canada
    Posts
    3,494

    NeoTherapeutics Reverse Stock split - 25:1

    NeoTherapeutics' Stockholders Approve Reverse Stock Split and Proposal for New Financings
    Trading on post-split basis to commence September 6, 2002
    Thursday September 5, 2:41 pm ET


    IRVINE, Calif., Sept. 5 /PRNewswire-FirstCall/-- NeoTherapeutics Inc. (Nasdaq: NEOT - News), announced today that its stockholders have approved an amendment to the Company's certificate of incorporation to effect a 25-for-1 reverse split of the Company's common stock. Approximately 86 percent of shares outstanding were voted in favor of the reverse split. Commencing Friday, September 6th, the Company's stock will trade on a post- split basis under the interim trading symbol of "NEOTD" for 20 trading days to assist in making investors aware of the split. After the end of this period, the trading symbol will revert to "NEOT".
    The stockholders of the Company also approved the raising, as necessary, of up to $10,000,000, through the issuance of the Company's common stock and/or warrants exercisable for the purchase of common stock, up to a maximum of 10,000,000 shares of common stock, potentially at discounts to the then current market price.

    "We are pleased with the approval of both proposals and the commitment our shareholders have demonstrated to the Company and our management team," said Rajesh Shrotriya, Chairman of the Board, Chief Executive Officer and President of NeoTherapeutics. During the meeting, Dr. Shrotriya provided shareholders with an update of the Company's operations including announcing that the Company has achieved its target to reduce the cash burn rate to below $500,000 per month. In addition, Dr. Shrotriya announced that he and the top two officers of the Company agreed to defer one hundred percent of their salary until the Company obtains additional financings.

    The Company currently has approximately 39,752,812 shares of common stock outstanding. Following the reverse split, there will be approximately 1,590,112 shares outstanding, subject to rounding for fractional shares.

    In the reverse stock split, each twenty-five shares of the Company's old common stock issued and outstanding will be automatically converted into one new share of common stock. Fractional shares of stock will not be issued as a result of the reverse split. Stockholders who would otherwise receive a fractional share of common stock will be entitled to receive an equivalent amount of cash in lieu of fractional shares, based on the closing price of the common stock on September 5, 2002. As a result, each stockholder who owns less than 25 shares of common stock immediately before the reverse stock split will no longer be a stockholder after the reverse stock split. Stockholders will receive instructions by mail regarding the method of exchanging the old stock certificates for new stock certificates. U.S. Stock Transfer Corporation, the Company's transfer agent, will act as the exchange agent for the purpose of implementing the exchange of stock certificates in relation to the reverse stock split.

    In addition, the number of shares of common stock reserved under the Company's stock option plans and for issuance pursuant to warrants to purchase the Company's common stock, the number of shares of common stock subject to those options and warrants and the terms of each outstanding option and warrant to purchase common stock will be adjusted to reflect the reverse stock split.

    NeoTherapeutics seeks to create value for shareholders through the in- licensing and commercialization of anti-cancer drugs and the discovery and out-licensing of drugs for central nervous system disorders. Satraplatin, the Company's lead oncology drug, is being prepared for a phase 3 study in prostate cancer. Additional anti-cancer drugs are in phase 1 and 2 stages of development for bladder cancer and non-Hodgkin's lymphoma. The Company has pre-clinical neurological drug candidates for disorders such as attention deficit hyperactivity disorder, schizophrenia, dementia, mild cognitive impairment, anxiety and pain. For additional information visit the Company's web site at www.neot.com.
    This press release may contain forward-looking statements regarding future events and the future performance of NeoTherapeutics that involve risks and uncertainties that could cause actual results to differ materially. These risks are described in further detail in the Company's reports filed with the Securities and Exchange Commission.

  2. #2
    Senior Member Max's Avatar
    Join Date
    Jul 2001
    Location
    Montreal,Province of Quebec, CANADA
    Posts
    15,036

    Mike

    I did not get it:Is it good news or bad?

    ==============================
    "Experience teaches that, of all the emotions, fear stands alone in its power to move us, or to capture us in its grip forever. In a world of terrors, there is nothing more fearsome that the unknown...especially when what is unknown is ourselves." Outer Limits(Fear Itself)



  3. #3
    Senior Member mk99's Avatar
    Join Date
    Jul 2001
    Location
    toronto, canada
    Posts
    3,494

    Max

    It's neither good nor bad. Here's my $.02

    Good - it means that instead of trading at $.10 the stock will now theoretically be trading at $2.50
    Stocks that are under $1 for a while are at some risk of being removed from the major stock exchanges... this would remove that risk. It may also show up on radar screens of institutional buyers. (ie: mutual funds, pension funds, etc). The vast majority of money in market is institutional. Most institutions will not look at buying $.10 stocks... in fact their cutoff may very well be $5.

    Neutral - assuming the stock starts trading at $2.50, the net result to shareholders would be neutral. Each share is worth more but there are far less shares

    Bad - it may put more downwards pressure on the stock... if a company is growing and doing great it will do a stock split... a reverse stock split clearly shows that company is having problems. It may bring out more short-sellers.

    OK?

  4. #4
    Senior Member Max's Avatar
    Join Date
    Jul 2001
    Location
    Montreal,Province of Quebec, CANADA
    Posts
    15,036

    Thank you,

    Mike very much

    ==============================
    "Experience teaches that, of all the emotions, fear stands alone in its power to move us, or to capture us in its grip forever. In a world of terrors, there is nothing more fearsome that the unknown...especially when what is unknown is ourselves." Outer Limits(Fear Itself)



  5. #5
    From my knowlege of stocks this is bad news. I am not judging what the company does. Only the reverse split. Typically stocks that reverse split do not survive. This comment is based on percentages only. I also noted the planned issuance of additional shares. This dilutes the value of the stock further. Not a good sign.

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •